Trials / Unknown
UnknownNCT05426018
The Efficacy and Safety of Different Doses of SY-009 in Patients With Type 2 Diabetes Mellitus
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial Evaluate the Efficacy and Safety of Oral Administration of Different Doses of SY-009 Capsule in Patients With T2DM for 12 Weeks
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Suzhou Yabao Pharmaceutical R&D Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
SY-009 is a novel compound that inhibits sodium glucose cotransporter-1 (SGLT-1). The preclinical and phase 1 clinical trial data support to carry out phase II clinical trial in diabetes subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SY-009 capsules | 3 capsules each time (3 test drugs), 3 times a day (oral administration before breakfast, lunch, dinner or with meals) |
Timeline
- Start date
- 2022-07-01
- Primary completion
- 2023-06-30
- Completion
- 2023-10-01
- First posted
- 2022-06-21
- Last updated
- 2022-06-21
Locations
7 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05426018. Inclusion in this directory is not an endorsement.